Use of composition for inhibiting activity of TAK1 and for manufacturing medicament for treating peritoneal fibrosis, and used in kit as biomarker for determining peritoneal fibrosis and determining progression of peritoneal fibrosis

Abstract: NOVELTY - Use of a composition is claimed for inhibiting activity of TAK1 and for manufacturing a medicament for treating peritoneal fibrosis, where the composition comprises an agent. USE - Used for inhibiting activity of TAK1 and for manufacturing a medicament for treating peritoneal fibrosis, and used in a kit as a biomarker for determining peritoneal fibrosis and determining progression of peritoneal fibrosis in a biological sample of mammal (all claimed). ADVANTAGE - The composition prevents and reverses mesenchymal-epithelial transition of peritoneum during peritoneal dialysis treatment. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a method for diagnosis and prognosis of peritoneal fibrosis, which involves obtaining a biological sample from mammal; and detecting and quantifying product of expression of TAK1 or its fragment or active molecule; and (2) a method for determining progression of peritoneal fibrosis, which involves determining concentration or activity of expression product of TAK1 or its fragment in a biological sample, which is isolated from mammal; (3) determining another concentration or activity of expression product of previously obtained product in a biological sample; and (4) comparing difference between both concentrations of the product to find a significant deviation.